Cryoport (NASDAQ:CYRX) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$45.5m (down 21% from 2Q 2024).
- Net loss: US$10.2m (loss narrowed by 87% from 2Q 2024).
- US$0.20 loss per share (improved from US$1.62 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cryoport Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 8.9%. Earnings per share (EPS) also surpassed analyst estimates.
Looking ahead, revenue is expected to decline by 1.7% p.a. on average during the next 3 years, while revenues in the Life Sciences industry in the US are expected to grow by 6.0%.
Performance of the American Life Sciences industry.
The company's shares are up 16% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Cryoport has 3 warning signs we think you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Cryoport might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.